Boulder-based Clovis (Nasdaq: CLVS) is in the process of testing CO-1686, an oral targeted inhibitor of mutant forms of an epidermal growth-factor receptor for the treatment of non-small-cell lung cancer, according to the company. The testing is referred to as TIGER2.
“The CO-1686 data observed to date have been highly consistent, including the growing evidence of a lengthy duration of benefit and the tolerability profile of the drug,´ said Patrick J. Mahaffy, president and CEO of Clovis, in a statement.
The company plans on filing a new drug application by mid-2015, after several more months of testing.
Testing of CO-1686 first occurred in Japan in the first quarter.